Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells (original) (raw)
Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Sawyers CL . Clinical efficacy and safety of an Abl-specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia Blood 1999 94: (Suppl. 1) 368a Google Scholar
Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, Ho AD, Zeller WJ . Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors Cancer Chemother Pharmacol 1999 44: 433–438 ArticleCASPubMed Google Scholar
Schiedlmeier B, Kühlcke K, Eckert HG, Baum C, Zeller WJ, Fruehauf S . Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice Blood 2000 95: 1237–1248 CASPubMed Google Scholar
Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S . An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology Blood 1999 94: 1517–1536 CASPubMed Google Scholar
Carlo-Stella C, Mangoni L, Almici C, Caramatti C, Cottafavi L, Dotti GP, Rizzoli V . Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide Bone Marrow Transplant 1994 14: 425–432 CASPubMed Google Scholar
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay J Immunol Meth 1983 65: 55–63 ArticleCAS Google Scholar
Finlay GJ, Wilson WR, Baguley BC . Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukemia cell lines Eur J Cancer Clin Oncol 1986 22: 655–662 ArticleCASPubMed Google Scholar
Pieters B, Huismans DR, Leyva A, Veerman AJP . Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia Cancer Letters 1988 41: 323–332 ArticleCASPubMed Google Scholar
Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984 22: 27–55 ArticleCASPubMed Google Scholar
Nowell PC, Hungerford DA . A minute chromosome in chronic granulocytic leukemia Science 1960 132: 1497–1501 Google Scholar
Rowley JD . A new consistant chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine, fluorescence and Giemsa staining Nature 1973 243: 290–293 ArticleCASPubMed Google Scholar
Konopka JB, Watanabe SM, Witte ON . An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity Cell 1984 37: 1035–1042 ArticleCASPubMed Google Scholar
Sawyers CL, Denny CT, Witte ON . Leukemia and the disruption of normal hematopoiesis Cell 1991 64: 337–350 ArticleCASPubMed Google Scholar
Warmuth M, Danhauser-Riedl S, Hallek M . Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies Ann Hematol 1999 78: 49–64 ArticleCASPubMed Google Scholar
McGahon A, Bissonette R, Schmitt M, Cotter KM, Green DR, Cotter TG . BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death Blood 1994 83: 1179–1187 CASPubMed Google Scholar
Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ . BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents Blood 1995 86: 1148–1158 CASPubMed Google Scholar
Nishii K, Kabarowski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF . ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block Oncogene 1996 13: 2225–2234 CASPubMed Google Scholar
McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR . Regulation of the Fas apoptotic cell death pathway by Abl J Biol Chem 1995 270: 22625–22631 ArticleCASPubMed Google Scholar
Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ . Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia Blood 1994 83: 2038–2044 CASPubMed Google Scholar
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of bcr/abl positive cells Nat Med 1996 2: 561–566 ArticleCASPubMed Google Scholar
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB . Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 1996 56: 100–104 CASPubMed Google Scholar
Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ . CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins Blood 1997 90: 4947–4952 CASPubMed Google Scholar
Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB . Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 2000 295: 139–145 CASPubMed Google Scholar
Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB . Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis Blood Cells Mol Dis 1997 23: 380–394 ArticleCASPubMed Google Scholar
Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL . Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL J Exp Med 2000 191: 977–984 ArticleCASPubMedPubMed Central Google Scholar
le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C . Induction of resistance to the abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 2000 95: 1758–1766 CASPubMed Google Scholar
Mahon FX, Deininger DWN, Schultheis B, Goldman JM, Melo JV . Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the signal transduction inhibitor STI571: mechanisms of resistance Blood 1999 94: (Suppl. 1) 656a Google Scholar
Lin CK, Nguyen TT, Morgan TL, Mei RL, Kaptein JS, Kalunta CI, Yen CF, Park E, Zou HY, Lad PM . Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM Exp Cell Res 1998 244: 1–13 ArticleCASPubMed Google Scholar
Johnson KR, Young KK, Fan W . Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy Clin Cancer Res 1999 5: 2559–2565 CASPubMed Google Scholar
Zeller WJ, Berger M, Schmähl D . Synergistic action of vincristine and adriamycin in the treatment of experimental rat leukemia L5222 Cancer Res 1979 39: 1071–1073 CASPubMed Google Scholar
Zeller WJ, Berger MR, Henne T, Weber E . More than additive toxicity of the combination of 1-methyl-1-nitrosourea plus 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat Cancer Res 1986 46: 1714–1716 CASPubMed Google Scholar